VNDA Stock Analysis: Buy, Sell, or Hold?
VNDA - Vanda Pharmaceuticals Inc.
$6.65
-0.26 (-3.76%)
▼
5d:
-5.0%
30d:
-25.36%
90d:
-5.54%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
VNDA is down 5.1% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 1,432 OI. Call ratio: 98% View Scanner →
Strength: 7.3/10
Get Alerted When VNDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: VNDA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: VNDA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: VNDA is currently trading at $6.65, which is considered oversold relative to its 30-day fair value range of $7.00 to $8.93.
Technical Outlook: Technically, VNDA is in a strong uptrend. The price is currently testing key support at $6.62. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.50 (+124.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VNDA is in a strong uptrend. The price is currently testing key support at $6.62. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.50 (+124.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$7.00 -
$8.93
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 124.3% below Wall St target ($15.50)
Fair Price Analysis
30-Day Fair Range
$7.00 -
$8.93
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$6.62
Resistance Level
$9.11
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.72
Wall Street Target
$15.50
(+124.3%)
Revenue Growth (YoY)
7.6%
Earnings Growth (YoY)
-95.9%
Profit Margin
-102.0%
Share & Embed Analysis
Last updated: March 30, 2026 5:00 PM ET
Data refreshes hourly during market hours. Next update: 6:00 PM
Data refreshes hourly during market hours. Next update: 6:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VNDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Gunther Birznieks
SELL
42431 shares
2026-03-02
Joakim Wijkstrom
SELL
30800 shares
2026-03-02
Kevin Patrick Moran
SELL
42442 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 58 HOLD |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 67 BUY |
